Didanosine causes sensory neuropathy in an HIV/AIDS animal model

Impaired mitochondrial and neurotrophic factor gene expression

Yu Zhu, Joseph M. Antony, Jose A. Martinez, D. Moira Glerum, Valentine Brussee, Ahmet Hoke, Douglas Zochodne, Christopher Power

Research output: Contribution to journalArticle

Abstract

Antiretroviral toxic neuropathy (ATN) has become a common peripheral neuropathy among HIV/AIDS patients, for which the underlying pathogenesis is uncertain. Indeed, no models exist for ATN that assess the interaction between retroviral infection and antiretroviral therapy. Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. We investigated neuronal morphology, neurobehavioural testing, viral load, mitochondrial and neurotrophic factor gene expression after ddI treatment of FIV-infected and uninfected animals or dorsal root ganglia (DRG) cultures. ddI caused concentration-dependent neuronal injury in cultured feline DRGs (P <0.05), together with reduced viral replication and diminished expression of mitochondrial cytochrome C oxidase subunit I gene (mtCOX I) and the neurotrophin, brain-derived neurotrophic factor (BDNF). Indeed, BDNF treatment reversed neuronal injury caused by FIV infection in the presence or absence of ddI exposure (P <0.05). In vivo FIV infection revealed delays in withdrawal latency to a noxious stimulus, which were exacerbated by ddI treatment. Epidermal density of nerve endings was reduced after FIV infection (P <0.05), especially with ddI treatment. Although viral replication in blood was suppressed in ddI-treated animals (P <0.05), ddI had a limited effect on viral abundance in DRGs of the same animals. ddI decreased mtCOX I expression in DRG neurons of FIV-infected animals (P <0.05). BDNF expression was downregulated by ddI in DRG Schwann cells following FIV infection. Thus, ddI treatment during FIV infection resulted in additive pathogenic effects contributing to the development of ATN, which was associated with mitochondrial injury on neurons and reduced BDNF production by Schwann cells in DRGs, highlighting the convergent pathogenic effects that antiretroviral drugs might have in patients with HIV infection.

Original languageEnglish (US)
Pages (from-to)2011-2023
Number of pages13
JournalBrain
Volume130
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Didanosine
Nerve Growth Factors
Feline Immunodeficiency Virus
Acquired Immunodeficiency Syndrome
Animal Models
HIV
Gene Expression
Poisons
Virus Diseases
Brain-Derived Neurotrophic Factor
Diagnosis-Related Groups
Spinal Ganglia
Schwann Cells
Wounds and Injuries
Neurons
Lentivirus Infections
Therapeutics
Nerve Endings
Felidae
Peripheral Nervous System Diseases

Keywords

  • BDNF
  • Didanosine
  • FIV
  • HIV
  • Mitochondria
  • Neuropathy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Didanosine causes sensory neuropathy in an HIV/AIDS animal model : Impaired mitochondrial and neurotrophic factor gene expression. / Zhu, Yu; Antony, Joseph M.; Martinez, Jose A.; Glerum, D. Moira; Brussee, Valentine; Hoke, Ahmet; Zochodne, Douglas; Power, Christopher.

In: Brain, Vol. 130, No. 8, 08.2007, p. 2011-2023.

Research output: Contribution to journalArticle

Zhu, Y, Antony, JM, Martinez, JA, Glerum, DM, Brussee, V, Hoke, A, Zochodne, D & Power, C 2007, 'Didanosine causes sensory neuropathy in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic factor gene expression', Brain, vol. 130, no. 8, pp. 2011-2023. https://doi.org/10.1093/brain/awm148
Zhu, Yu ; Antony, Joseph M. ; Martinez, Jose A. ; Glerum, D. Moira ; Brussee, Valentine ; Hoke, Ahmet ; Zochodne, Douglas ; Power, Christopher. / Didanosine causes sensory neuropathy in an HIV/AIDS animal model : Impaired mitochondrial and neurotrophic factor gene expression. In: Brain. 2007 ; Vol. 130, No. 8. pp. 2011-2023.
@article{1c17d276fe254f1795bd282f036e4cd7,
title = "Didanosine causes sensory neuropathy in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic factor gene expression",
abstract = "Antiretroviral toxic neuropathy (ATN) has become a common peripheral neuropathy among HIV/AIDS patients, for which the underlying pathogenesis is uncertain. Indeed, no models exist for ATN that assess the interaction between retroviral infection and antiretroviral therapy. Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. We investigated neuronal morphology, neurobehavioural testing, viral load, mitochondrial and neurotrophic factor gene expression after ddI treatment of FIV-infected and uninfected animals or dorsal root ganglia (DRG) cultures. ddI caused concentration-dependent neuronal injury in cultured feline DRGs (P <0.05), together with reduced viral replication and diminished expression of mitochondrial cytochrome C oxidase subunit I gene (mtCOX I) and the neurotrophin, brain-derived neurotrophic factor (BDNF). Indeed, BDNF treatment reversed neuronal injury caused by FIV infection in the presence or absence of ddI exposure (P <0.05). In vivo FIV infection revealed delays in withdrawal latency to a noxious stimulus, which were exacerbated by ddI treatment. Epidermal density of nerve endings was reduced after FIV infection (P <0.05), especially with ddI treatment. Although viral replication in blood was suppressed in ddI-treated animals (P <0.05), ddI had a limited effect on viral abundance in DRGs of the same animals. ddI decreased mtCOX I expression in DRG neurons of FIV-infected animals (P <0.05). BDNF expression was downregulated by ddI in DRG Schwann cells following FIV infection. Thus, ddI treatment during FIV infection resulted in additive pathogenic effects contributing to the development of ATN, which was associated with mitochondrial injury on neurons and reduced BDNF production by Schwann cells in DRGs, highlighting the convergent pathogenic effects that antiretroviral drugs might have in patients with HIV infection.",
keywords = "BDNF, Didanosine, FIV, HIV, Mitochondria, Neuropathy",
author = "Yu Zhu and Antony, {Joseph M.} and Martinez, {Jose A.} and Glerum, {D. Moira} and Valentine Brussee and Ahmet Hoke and Douglas Zochodne and Christopher Power",
year = "2007",
month = "8",
doi = "10.1093/brain/awm148",
language = "English (US)",
volume = "130",
pages = "2011--2023",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Didanosine causes sensory neuropathy in an HIV/AIDS animal model

T2 - Impaired mitochondrial and neurotrophic factor gene expression

AU - Zhu, Yu

AU - Antony, Joseph M.

AU - Martinez, Jose A.

AU - Glerum, D. Moira

AU - Brussee, Valentine

AU - Hoke, Ahmet

AU - Zochodne, Douglas

AU - Power, Christopher

PY - 2007/8

Y1 - 2007/8

N2 - Antiretroviral toxic neuropathy (ATN) has become a common peripheral neuropathy among HIV/AIDS patients, for which the underlying pathogenesis is uncertain. Indeed, no models exist for ATN that assess the interaction between retroviral infection and antiretroviral therapy. Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. We investigated neuronal morphology, neurobehavioural testing, viral load, mitochondrial and neurotrophic factor gene expression after ddI treatment of FIV-infected and uninfected animals or dorsal root ganglia (DRG) cultures. ddI caused concentration-dependent neuronal injury in cultured feline DRGs (P <0.05), together with reduced viral replication and diminished expression of mitochondrial cytochrome C oxidase subunit I gene (mtCOX I) and the neurotrophin, brain-derived neurotrophic factor (BDNF). Indeed, BDNF treatment reversed neuronal injury caused by FIV infection in the presence or absence of ddI exposure (P <0.05). In vivo FIV infection revealed delays in withdrawal latency to a noxious stimulus, which were exacerbated by ddI treatment. Epidermal density of nerve endings was reduced after FIV infection (P <0.05), especially with ddI treatment. Although viral replication in blood was suppressed in ddI-treated animals (P <0.05), ddI had a limited effect on viral abundance in DRGs of the same animals. ddI decreased mtCOX I expression in DRG neurons of FIV-infected animals (P <0.05). BDNF expression was downregulated by ddI in DRG Schwann cells following FIV infection. Thus, ddI treatment during FIV infection resulted in additive pathogenic effects contributing to the development of ATN, which was associated with mitochondrial injury on neurons and reduced BDNF production by Schwann cells in DRGs, highlighting the convergent pathogenic effects that antiretroviral drugs might have in patients with HIV infection.

AB - Antiretroviral toxic neuropathy (ATN) has become a common peripheral neuropathy among HIV/AIDS patients, for which the underlying pathogenesis is uncertain. Indeed, no models exist for ATN that assess the interaction between retroviral infection and antiretroviral therapy. Herein, we developed ex vivo and in vivo models of ATN induced by didanosine (ddI) following infection by the lentivirus, feline immunodeficiency virus (FIV), permitting us to address the working hypothesis that ddI mediates ATN through mitochondrial injury in neurons. We investigated neuronal morphology, neurobehavioural testing, viral load, mitochondrial and neurotrophic factor gene expression after ddI treatment of FIV-infected and uninfected animals or dorsal root ganglia (DRG) cultures. ddI caused concentration-dependent neuronal injury in cultured feline DRGs (P <0.05), together with reduced viral replication and diminished expression of mitochondrial cytochrome C oxidase subunit I gene (mtCOX I) and the neurotrophin, brain-derived neurotrophic factor (BDNF). Indeed, BDNF treatment reversed neuronal injury caused by FIV infection in the presence or absence of ddI exposure (P <0.05). In vivo FIV infection revealed delays in withdrawal latency to a noxious stimulus, which were exacerbated by ddI treatment. Epidermal density of nerve endings was reduced after FIV infection (P <0.05), especially with ddI treatment. Although viral replication in blood was suppressed in ddI-treated animals (P <0.05), ddI had a limited effect on viral abundance in DRGs of the same animals. ddI decreased mtCOX I expression in DRG neurons of FIV-infected animals (P <0.05). BDNF expression was downregulated by ddI in DRG Schwann cells following FIV infection. Thus, ddI treatment during FIV infection resulted in additive pathogenic effects contributing to the development of ATN, which was associated with mitochondrial injury on neurons and reduced BDNF production by Schwann cells in DRGs, highlighting the convergent pathogenic effects that antiretroviral drugs might have in patients with HIV infection.

KW - BDNF

KW - Didanosine

KW - FIV

KW - HIV

KW - Mitochondria

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=34547793113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547793113&partnerID=8YFLogxK

U2 - 10.1093/brain/awm148

DO - 10.1093/brain/awm148

M3 - Article

VL - 130

SP - 2011

EP - 2023

JO - Brain

JF - Brain

SN - 0006-8950

IS - 8

ER -